248 related articles for article (PubMed ID: 32065102)
1. A Protective Role of Translocator Protein in Alzheimer's Disease Brain.
Jung ME
Curr Alzheimer Res; 2020; 17(1):3-15. PubMed ID: 32065102
[TBL] [Abstract][Full Text] [Related]
2. Translocator protein (TSPO) role in aging and Alzheimer's disease.
Repalli J
Curr Aging Sci; 2014; 7(3):168-75. PubMed ID: 25495567
[TBL] [Abstract][Full Text] [Related]
3. TSPO Ligands Boost Mitochondrial Function and Pregnenolone Synthesis.
Lejri I; Grimm A; Hallé F; Abarghaz M; Klein C; Maitre M; Schmitt M; Bourguignon JJ; Mensah-Nyagan AG; Bihel F; Eckert A
J Alzheimers Dis; 2019; 72(4):1045-1058. PubMed ID: 31256132
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies.
Grimm A; Lejri I; Hallé F; Schmitt M; Götz J; Bihel F; Eckert A
J Neuroendocrinol; 2020 Jan; 32(1):e12796. PubMed ID: 31536662
[TBL] [Abstract][Full Text] [Related]
5. Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18 kDa translocator protein (TSPO) in a mouse model of Alzheimer's disease.
Pradhan AK; Neumüller T; Klug C; Fuchs S; Schlegel M; Ballmann M; Tartler KJ; Pianos A; Garcia MS; Liere P; Schumacher M; Kreuzer M; Rupprecht R; Rammes G
Transl Psychiatry; 2023 Oct; 13(1):332. PubMed ID: 37891168
[TBL] [Abstract][Full Text] [Related]
6. The role of 18 kDa mitochondrial translocator protein (TSPO) in programmed cell death, and effects of steroids on TSPO expression.
Veenman L; Gavish M
Curr Mol Med; 2012 May; 12(4):398-412. PubMed ID: 22348610
[TBL] [Abstract][Full Text] [Related]
7. Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
Kim T; Yang HY; Park BG; Jung SY; Park JH; Park KD; Min SJ; Tae J; Yang H; Cho S; Cho SJ; Song H; Mook-Jung I; Lee J; Pae AN
Eur J Med Chem; 2017 Jan; 125():1172-1192. PubMed ID: 27855359
[TBL] [Abstract][Full Text] [Related]
8. The Ligands of Translocator Protein: Design and Biological Properties.
Mokrov GV; Deeva OA; Gudasheva TA
Curr Pharm Des; 2021; 27(2):217-237. PubMed ID: 32881658
[TBL] [Abstract][Full Text] [Related]
9. Development of new treatments for Alzheimer's disease based on the modulation of translocator protein (TSPO).
Arbo BD; Ribeiro MF; Garcia-Segura LM
Ageing Res Rev; 2019 Sep; 54():100943. PubMed ID: 31430564
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells.
Bader S; Wolf L; Milenkovic VM; Gruber M; Nothdurfter C; Rupprecht R; Wetzel CH
Psychoneuroendocrinology; 2019 Aug; 106():65-76. PubMed ID: 30954920
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains.
Gui Y; Marks JD; Das S; Hyman BT; Serrano-Pozo A
Brain Pathol; 2020 Jan; 30(1):151-164. PubMed ID: 31276244
[TBL] [Abstract][Full Text] [Related]
12. The changing landscape in translocator protein (TSPO) function.
Selvaraj V; Stocco DM
Trends Endocrinol Metab; 2015 Jul; 26(7):341-8. PubMed ID: 25801473
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases.
Arbo BD; Benetti F; Garcia-Segura LM; Ribeiro MF
J Steroid Biochem Mol Biol; 2015 Nov; 154():68-74. PubMed ID: 26200949
[TBL] [Abstract][Full Text] [Related]
14. The translocator protein (TSPO): a novel target for cancer chemotherapy.
Austin CJ; Kahlert J; Kassiou M; Rendina LM
Int J Biochem Cell Biol; 2013 Jul; 45(7):1212-6. PubMed ID: 23518318
[TBL] [Abstract][Full Text] [Related]
15. 18-kDa translocator protein association complexes in the brain: From structure to function.
Costa B; Da Pozzo E; Martini C
Biochem Pharmacol; 2020 Jul; 177():114015. PubMed ID: 32387458
[TBL] [Abstract][Full Text] [Related]
16. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis.
Veenman L; Shandalov Y; Gavish M
J Bioenerg Biomembr; 2008 Jun; 40(3):199-205. PubMed ID: 18670869
[TBL] [Abstract][Full Text] [Related]
17. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.
Papadopoulos V; Lecanu L
Exp Neurol; 2009 Sep; 219(1):53-7. PubMed ID: 19409385
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements to obtain highly potent and selective 18 kDa Translocator Protein (TSPO) Ligands.
Taliani S; Pugliesi I; Da Settimo F
Curr Top Med Chem; 2011; 11(7):860-86. PubMed ID: 21291396
[TBL] [Abstract][Full Text] [Related]
19. An update into the medicinal chemistry of translocator protein (TSPO) ligands.
Barresi E; Robello M; Costa B; Da Pozzo E; Baglini E; Salerno S; Da Settimo F; Martini C; Taliani S
Eur J Med Chem; 2021 Jan; 209():112924. PubMed ID: 33081988
[TBL] [Abstract][Full Text] [Related]
20. TSPO ligand PK11195 improves Alzheimer-related outcomes in aged female 3xTg-AD mice.
Christensen A; Pike CJ
Neurosci Lett; 2018 Sep; 683():7-12. PubMed ID: 29925037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
